Opdivo Turned Down By NICE In Head And Neck Cancer
Executive Summary
BMS looks unlikely to have a positive NICE opinion synchronized with European approval of Opdivo in head and neck cancer, after the HTA body turned down the checkpoint inhibitor in its draft appraisal.